NASDAQ: $HALO Ensuring Long-Term Revenue Predictability In a significant announcement for stakeholders, Halozyme Therapeutics has officially reaffirmed its financial outlook regarding the impact of the Medicare Drug Price Negotiation Program. Despite evolving regulatory landscapes, the company projects zero to minimal impact on its royalty revenue through at least 2035. Understanding the Regulatory Context The company’s…